title: Impact of multimodal therapy on the survival of patients with newly diagnosed uterine carcinosarcoma.
abstract: OBJECTIVE
  To investigate treatment outcomes of uterine carcinosarcoma (CS) patients who underwent complete surgical resection of all visible disease and platinum-based adjuvant chemotherapy (multimodal therapy).
  
  
  METHODS
  The authors reviewed 127 uterine CS patients treated at this institution from 1990 to 2010. They operated 123 patients in clinical Stages 1-3, 97 of which underwent complete resection and systemic lymphadenectomy.
  
  
  RESULTS
  A total of 97 patients (FIGO 2008: Stage 1 in 50 patients, Stage 2 in six, Stage 3 in 37, and Stage 4 in four) underwent surgical staging, 74 of which were administered five cycles (median) of platinum-based adjuvant chemotherapy. The median overall survival (OS) associated with multimodal therapy 50.6 months compared with 34.9 months incomplete multimodal therapy. After multimodal treatment, 32.9% (32/97) patients showed recurrence (24/32 hematogenous).
  
  
  CONCLUSIONS
  Multimodal therapy increased survival among uterine CS patients, but the recurrence rate remained high. Further consideration of treatment options for uterine CS is required.
authors.affiliation: Department of Gynecology, Cancer Institute Hospital, Kotou-Ku, Japan. hiroko.machida@jfcr.or.jp
authors.forename: H
authors.initials: H
authors.lastname: Machida
authors.forename: K
authors.initials: K
authors.lastname: Takahashi
authors.forename: H
authors.initials: H
authors.lastname: Nomura
authors.forename: M
authors.initials: M
authors.lastname: Matoda
authors.forename: K
authors.initials: K
authors.lastname: Omatsu
authors.forename: K
authors.initials: K
authors.lastname: Kato
authors.forename: K
authors.initials: K
authors.lastname: Umayahara
authors.forename: N
authors.initials: N
authors.lastname: Takeshima
mesh_terms: D000328:Adult; D000368:Aged; D002296:Carcinosarcoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D014594:Uterine Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*